Rapid repigmentation of vitiligo with tofacitinib plus low-dose narrowband ultraviolet B (nbUVB), even following depigmentation with monobenzyl ether of hydroquinone

Background: Vitiligo is an autoimmune disease that results in disfiguring white patches of skin due to destruction of melanocytes via cell-mediated immunity. Recent advances in our understanding of vitiligo pathogenesis have led to Janus kinase (JAK) inhibitors, including tofacitinib, as a promising class of targeted therapy with IFN-γ and CD8+ T cells as important mediators.